Publicacións nas que colabora con Mónica Marazuela Azpiroz (46)

2024

  1. Consensus on criteria for acromegaly diagnosis and remission

    Pituitary, Vol. 27, Núm. 1, pp. 7-22

  2. ERRATUM: Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs

    Endocrine-related cancer

  3. Effectiveness of combined first-line medical treatment in acromegaly with prolactin cosecretion

    European Journal of Endocrinology, Vol. 190, Núm. 6, pp. 458-466

  4. Glucose metabolism outcomes after pituitary surgery in patients with acromegaly

    Pituitary, Vol. 27, Núm. 5, pp. 497-506

  5. Integrative clinical, hormonal, and molecular data associate with invasiveness in acromegaly: REMAH study

    European Journal of Endocrinology, Vol. 190, Núm. 6, pp. 421-433

  6. Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs

    Endocrine-Related Cancer, Vol. 31, Núm. 7

2023

  1. Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly

    Frontiers in Endocrinology, Vol. 14

2022

  1. Acromegaly disease activity according to ACRODAT®, a cross-sectional study in Spain: ACROVAL study

    Endocrine, Vol. 75, Núm. 2, pp. 525-536

  2. Data mining analyses for precision medicine in acromegaly: a proof of concept

    Scientific Reports, Vol. 12, Núm. 1

  3. Implications of Heterogeneity of Epithelial-Mesenchymal States in Acromegaly Therapeutic Pharmacologic Response

    Biomedicines, Vol. 10, Núm. 2

2021

  1. Molecular determinants of enhanced response to somatostatin receptor ligands after debulking in large GH-producing adenomas

    Clinical Endocrinology, Vol. 94, Núm. 5, pp. 811-819

  2. Pasireotide in the Personalized Treatment of Acromegaly

    Frontiers in Endocrinology, Vol. 12

2020

  1. A consensus on the diagnosis and treatment of acromegaly comorbidities: An update

    Journal of Clinical Endocrinology and Metabolism, Vol. 105, Núm. 4, pp. E937-E946

  2. Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly

    Endocrine, Vol. 70, Núm. 3, pp. 575-583

  3. Lat-1 and glut-1 carrier expression and its prognostic value in gastroenteropancreatic neuroendocrine tumors

    Cancers, Vol. 12, Núm. 10, pp. 1-18

  4. Molecular profiling for acromegaly treatment: a validation study

    Endocrine-related cancer, Vol. 27, Núm. 6, pp. 375-389

2018

  1. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

    The Lancet, Vol. 392, Núm. 10157, pp. 1519-1529

  2. Analysis of expression of the PD-1/PD-L1 immune checkpoint system and its prognostic impact in gastroenteropancreatic neuroendocrine tumors

    Scientific Reports, Vol. 8, Núm. 1

  3. Expert document on management of acromegaly

    Endocrinologia, Diabetes y Nutricion, Vol. 65, Núm. 8, pp. 428-437

2017

  1. Prevalence of acromegaly in patients with symptoms of sleep apnea

    PLoS ONE, Vol. 12, Núm. 9